JNJ JN

JNJ Johnson & Johnson

Healthcare · Drug Manufacturers - General

4 · Weak Momentum 9.0 · Strong Safe Aristocrat

259.80

-0.77%

About the company

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

2.06%
62.25%
5.36
626.1B
30.17
8.61
228.73

52-week range

260
low 173 high 275
Yield Growth Momentum Safety Value Health

Dividend deep dive

Johnson & Johnson (JNJ) is a healthcare sector company specializing in drug manufacturing with a market capitalization of USD 624.26 billion. The company currently provides a dividend yield of 2.13%. This yield is below its 5-year average of 2.88%, with yield theory suggesting an "overvalued" status for the stock. Despite this, Johnson & Johnson's dividend safety status is assessed as "safe".

Dividend history

Johnson & Johnson has demonstrated a consistent dividend growth record, earning it a "Champion" tier classification with 29 consecutive years of dividend increases. The dividend has grown at a 3-year Compound Annual Growth Rate (CAGR) of 4.78% and a 5-year CAGR of 5.18%. Dividends are distributed quarterly in March, June, September, and December. Annual dividends per share have increased steadily from USD 2.80 in 2014 to USD 4.96 in 2024, with a projected USD 5.20 for 2025.

Dividend safety

Johnson & Johnson's dividend is rated as "safe." The company maintains a payout ratio of 62.18% based on its current dividend and earnings per share. Its debt-to-equity ratio is 67.73%. Current and quick ratio figures were not provided.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.

Price history

258 197 137 2021 2022 2023 2024 2025 2026 2020-09 · 149 2020-10 · 137 2020-11 · 145 2020-12 · 157 2021-01 · 163 2021-02 · 158 2021-03 · 164 2021-04 · 163 2021-05 · 169 2021-06 · 165 2021-07 · 172 2021-08 · 173 2021-09 · 162 2021-10 · 163 2021-11 · 156 2021-12 · 171 2022-01 · 172 2022-02 · 165 2022-03 · 177 2022-04 · 180 2022-05 · 180 2022-06 · 178 2022-07 · 175 2022-08 · 161 2022-09 · 163 2022-10 · 174 2022-11 · 178 2022-12 · 177 2023-01 · 163 2023-02 · 153 2023-03 · 155 2023-04 · 164 2023-05 · 155 2023-06 · 166 2023-07 · 168 2023-08 · 162 2023-09 · 156 2023-10 · 148 2023-11 · 155 2023-12 · 157 2024-01 · 159 2024-02 · 161 2024-03 · 158 2024-04 · 145 2024-05 · 147 2024-06 · 146 2024-07 · 158 2024-08 · 166 2024-09 · 162 2024-10 · 160 2024-11 · 155 2024-12 · 145 2025-01 · 152 2025-02 · 165 2025-03 · 166 2025-04 · 156 2025-05 · 155 2025-06 · 153 2025-07 · 165 2025-08 · 177 2025-09 · 185 2025-10 · 189 2025-11 · 207 2025-12 · 207 2026-01 · 227 2026-02 · 248 2026-03 · 244 2026-04 · 230 2026-05 · 225 2026-06 · 254 2026-07 · 256 2026-08 · 258
Price

Dividend profile

Frequency
Quarterly
Growth (TTM)
+4.4%
CAGR 3y
+4.8%
+5.2%
29 years

(5-year)

Now 2.1%
2.6% avg 2.9% 3.2%

Payment calendar

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Dividend history

CAGR 3y +4.8% CAGR 5y +5.2% 29y streak
14 15 16 17 18 19 20 21 22 23 24 25

Per-share dividend by year

Quantic · Free

Unlock valuation & strategy

Two DDM fair values, margin of safety, sector value rank, Dividend Yield Theory, doubling time and max drawdown.

Debt & leverage

57.7%
1.09
0.73
Debt vs cash
Debt Cash
Total debt
49.0B USD
Total cash
20.8B USD
34.9B USD

Latest reported balance-sheet figures.

Held by 23 investors · watched by 5

Appears in these comparisons

See how JNJ stacks up against its dividend rivals.

Information, not financial advice.

Quantic · Free

Track JNJ and your whole portfolio

Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.

€0

Need more? Pro adds portfolios, options income tracking & more AI. See Pro →